Erratum to: Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice

Vivian P. Bykerk, Andrew J.k. Östör, José María Álvaro‐Gracia, Karel Pavelká, Jose Andrés Román Ivorra, W. Graninger, W. Bensen, Michael T. Nurmohamed, Andreas Krause, Corrado Bernasconi, Maher Aassi, Jean SibiliaClinical 2015 · DOI · OpenAlex

TL;DR

This document is a formal erratum (correction) for a clinical study evaluating tocilizumab for rheumatoid arthritis. The critical update clarifies that patients on tocilizumab monotherapy actually experienced lower—not higher—incidences of specific laboratory abnormalities (transaminase elevations and neutropenia) compared to those on combination therapy.

What Problem Does This Paper Address?

In clinical research, the precision of language is as vital as the precision of the data itself. This erratum addresses a significant typographical error in the "Discussion" section of a previously published study: Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.

The original study aimed to determine if tocilizumab (a biological drug that blocks the IL-6 receptor) works better alone or in combination with traditional disease-modifying antirheumatic drugs (DMARDs) for patients who haven't found relief with other treatments. Because these treatments can affect liver function and white blood cell counts, accurately reporting the safety profile is essential for clinicians making prescribing decisions.

Methods

As this document is an erratum, it does not introduce new experimental methods. However, it references the original study’s design: an open-label study designed to mimic "real-world" clinical practice.

In the context of this correction, the "method" involved a post-publication review of the text against the raw data, identifying a directionality error in the Discussion section where the word "higher" was mistakenly used instead of "lower."

Datasets

The original study involved a cohort of patients with rheumatoid arthritis who had shown inadequate responses to previous treatments. While specific sample sizes and demographic breakdowns are not detailed in this one-page erratum, the study compared two primary groups:

  1. Monotherapy Group: Patients receiving only tocilizumab.
  2. Combination Group: Patients receiving tocilizumab plus add-on DMARDs.

Key Insights and Ideas

The "aha moment" here is a reminder of how a single word can flip the interpretation of clinical safety data.

  • Directionality Matters: The correction clarifies that monotherapy was associated with lower incidences of transaminase elevations (an indicator of liver stress) and neutropenia (a decrease in a type of white blood cell) than combination therapy.
  • Safety Overlap: Despite the lower incidence in the monotherapy group, the authors emphasize that the overall safety profiles of both treatment arms overlapped. This suggests that while there are statistical differences in specific lab markers, the general risk-to-benefit ratio remains comparable between the two approaches.
  • Consistency with Controlled Trials: The corrected finding aligns this "real-world" study with results from more rigid, double-blind clinical trials (specifically referencing study [9] in their bibliography), reinforcing the validity of the observation.

Key Results

The primary quantitative takeaway from this correction is the shift in the safety narrative:

  • Transaminase Elevations & Neutropenia: Incidence rates were lower in the monotherapy group compared to the combination therapy group.
  • General Safety: The safety profiles for both groups were found to be consistent and overlapping, meaning no new major safety signals were identified that would drastically favor one treatment path over the other based solely on this study.

Limitations and Future Work

The authors acknowledge a common limitation in "close to clinical practice" studies: Statistical Power for Rare Events.

While the study could identify trends in common laboratory abnormalities like transaminase elevations, it was not large enough to provide a definitive comparison of "uncommon events." Specifically, the authors note that larger studies are required to accurately compare the rates of serious infections between monotherapy and combination therapy. This highlights a persistent challenge in rheumatology: balancing the need for real-world data with the massive sample sizes required to catch rare but serious side effects.

Summary updated

BibTeX
@inproceedings{bykerk2015erratum,
  author = {Vivian P. Bykerk and Andrew J.K. Östör and José María Álvaro‐Gracia and Karel Pavelká and Jose Andrés Román Ivorra and W. Graninger and W. Bensen and Michael T. Nurmohamed and Andreas Krause and Corrado Bernasconi and Maher Aassi and Jean Sibilia},
  title = {{Erratum to: Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice}},
  booktitle = {Clinical},
  year = {2015},
  doi = {10.1007/s10067-015-2932-z},
}
Figure